Journal
ONCOLOGY REPORTS
Volume 38, Issue 5, Pages 3055-3063Publisher
SPANDIDOS PUBL LTD
DOI: 10.3892/or.2017.5955
Keywords
MEK; breast cancer; migration; beta-catenin; nuclear accumulation
Categories
Funding
- National Science Foundation of Henan [162300410039]
- Department of Education of Henan Province [16A350013]
Ask authors/readers for more resources
Abnormal activation of the RAF/MEK/ERK signaling pathway has been observed in breast cancer. Thus, a number of MEK inhibitors have been designed as one treatment option for breast cancer. Although some studies have found that these MEK inhibitors inhibit the growth of a variety of human cancer cells, some trials have shown that the use of MEK inhibitors as a treatment for breast cancer does not adequately improve survival for unknown reasons. In the present study, MEK inhibitor PD98059 was used to evaluate its anticancer effects on human breast cancer MCF-7 and MDA-MB-231 cells and to explore the possible mechanism of action. Our results revealed that MEK inhibitor PD98059 exhibited antiproliferative effects in a dose-and time-dependent manner in MCF-7 and MDA-MB-231 breast cancer cells. Conversely, incubation of MCF-7 and MDA-MB-231 cells with PD98059 promoted their migration. Further investigation disclosed that the enhanced ability of migration promoted by PD98059 was dependent on beta-catenin nuclear translocation in the MCF-7 and MDA-MB-231 cells. Subsequent experiments documented that activation of EGFR signaling induced by PD98059 increased the amount of beta-catenin in the nucleus. Taken together, our findings may elucidate a possible mechanism explaining the ineffectiveness of MEK inhibitors in breast cancer treatment and improve our understanding of the role of MEK in cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available